Celldex Therapeutics, Inc. Deferred Income Tax Expense (Benefit)
Celldex Therapeutics, Inc. (CLDX) reported Deferred Income Tax Expense (Benefit) of -$5.20 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2017-11-07
- 2017-09-30: Deferred Income Tax Expense (Benefit) 9 month -$5.20M.
| Period end | Deferred Income Tax Expense (Benefit) 9 month |
|---|---|
| 2017-09-30 | -$5.20M 10-Q · filed 2017-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |